A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...

BeiGene Ltd. announced that the U.S. Patent and Trademark Office has invalidated all claims of a Pharmacyclics LLC patent that were challenged by BeiGene in a post-grant review proceeding. This ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office ...

Over the last 7 days, the United States market has risen by 7.1%, contributing to a 7.7% increase over the past year, with earnings growth anticipated at 14% per annum in the coming years. In this ...

An announcement from BeiGene Ltd ( ($HK:6160) ) is now available. BeiGene, Ltd. announced the successful passing of all resolutions at its ...

Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

Jing Yang was a Hong Kong-based senior correspondent for The Wall Street Journal covering M&A, IPOs, private equity and broad ...

Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.